32 results about "Betaine-aldehyde dehydrogenase" patented technology

The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles (e.g., for treating alcoholism in humans).

The invention discloses a primer and a detection method which can detect a screened molecular marker aiming at aromatic rice with multiple types of aroma genes and amplify a molecular marker of multiple types of betaine aldehyde dehydrogenase genes 2 (Badh2 / badh2) which are directly related to rice aroma formation. The detection method comprises the following steps: (1) extracting total DNAs of the rice as a template, and adding the primer for performing polymerase chain reaction (PCR) amplification; (2) performing restriction endonuclease Alu I digestion on a PCR product; (3) performing gel electrophoresis detection on an enzyme-digested product. The situation that only a mutation type of the aroma allele can be identified in the process of detecting a molecular marker of aroma genes in the past is broken, plants containing different types of the aroma genes can be selected in an assisted mode, a mutation type of the aroma allele of a parent aromatic rice variety is not required to determined before the operation of performing novel aromatic rice variety breeding on the molecular marker in an assisted mode, and pre-operation steps of molecular marker-assisted breeding are simplified, so that a breeding objective for breeding a novel aromatic rice variety is rapidly and effectively realized.

The invention discloses an application of acetaldehyde dehydrogenase 2 as a drug target for treating tumor cells with anthracycline type chemotherapy drugs. Drug screening shows that the anthracycline type chemotherapy drugs can specifically kill renal clear cell cancer cells with VHL deletion or mutation and has small toxicity to normal cells, thus providing an effective choice for chemotherapy of renal cancer and overcoming the disadvantage that the renal cancer is only treated through operations in clinical at present. Further study shows the sensitivity of the acetaldehyde dehydrogenase 2 mediated anthracycline type chemotherapy drugs to tumor cells, thus remaindering the application of the acetaldehyde dehydrogenase 2 as the drug target for treating tumor cells with the anthracycline type chemotherapy drugs. Deletion or mutation of the acetaldehyde dehydrogenase 2 exists in 40% of populations in Asia, so that the application of the acetaldehyde dehydrogenase 2 has a broader application prospect. For patients without the deletion or the mutation of the acetaldehyde dehydrogenase 2, killing effects on tumor cells can be significantly enhanced through combination of the anthracycline type chemotherapy drugs and an inhibitor of the acetaldehyde dehydrogenase 2.